Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 1677 other investors.
Svein Martin Bjørnstad, CFO in Carasent ASA, has through his wholly-ownedcompany Birgen Invest II AS, acquired 150,000 shares at NOK 13.76 per share.Following this trade Svein Martin Bjørnstad and associated companies holds intotal 280,249 shares in Carasent ASA.
Board member in Carasent ASA, Ulrika Cederskog Sundling, has today acquired6,000 shares in Carasent ASA at an average share price of NOK 16,79 per share.Following this trade her total shareholding in the Company is 6,000 shares.
Redeye updates its estimates following Carasent’s Q4 2022 report, which showed stronger growth than what we had anticipated. Moreover, the organic growth rate pace increased from the previous quarter. Investments still weighed down near-term margins, but management signaled that it seeks to slow down new hires and start scaling margins again, in a few quarters' time, to our understanding.
Read more and download the Research Update.
Attached please find Carasent Q4 and FY 2022 Financial Results and Presentation.
Carasent ASA will present its Q4 and FY 2022 Financial Results as a webcast onFebruary 15, at 8:00 a.m. Please use the following link for the webcast:https://channel.royalcast.com/landingpage/hegnarmedia/20230215_3/ Welcome.
Attached please find the proposal from the Company's Nomination Committee to theAnnual Shareholder Meeting.
Financial calendar for Carasent ASAFINANCIAL YEAR 202215.02.2023 - Quarterly Report - Q4FINANCIAL YEAR 202314.07.2023 - Half-yearly Report31.03.2023 - Annual Report03.05.2023 - Annual General Meeting04.05.2023 - Quarterly Report - Q126.10.2023 - Quarterly Report - Q315.02.2024 - Quarterly Report - Q4This information is published pursuant to the requirements set out in theContinuing obligations.
Redeye updates its estimates following Carasent’s Q3 report and the acquisitions of HPI and Confrere. The Q3 report came in below our estimates, and we are thus revising our near to medium-term estimates as a consequence.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
The new CEO Daniel Øhman has bought 8,500 shares in Carasent ASA for a totalamount of NOK 144,585 at an average share price of NOK 17.01 per share. Totalholding after this trade is 12,221 shares. For further informatio please contact:Svein Martin Bjørnstad, CFO, tel: +47 97969493